(Q40377702)

English

Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes

scientific article published on 17 January 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

http://europepmc.org/abstract/PMC/5432122

Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes (English)

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

http://europepmc.org/abstract/PMC/5432122

3-[2-butyl-1-[2-(diethylamino)ethyl]-5-benzimidazolyl]-N-hydroxy-2-propenamide

1 reference

ChEBI release 2020-05-28

Hagop Kantarjian

20

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

8

object named as

Farhad Ravandi

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

5

object named as

Elias Jabbour

1 reference

Europe PubMed Central

24 May 2018

PMC publication ID

Guillermo Garcia-Manero

1

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

24 May 2018

PMC publication ID

Jesus G Berdeja

3

object named as

Jesus G Berdeja

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

http://europepmc.org/abstract/PMC/5432122

11

object named as

Amy E DeZern

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

http://europepmc.org/abstract/PMC/5432122

Rami S Komrokji

16

object named as

Rami S Komrokji

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

http://europepmc.org/abstract/PMC/5432122

22

object named as

Gail J Roboz

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

http://europepmc.org/abstract/PMC/5432122

Mikkael A Sekeres

19

object named as

Mikkael A Sekeres

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

http://europepmc.org/abstract/PMC/5432122

Guillermo Montalban-Bravo

2

object named as

Guillermo Montalban-Bravo

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

http://europepmc.org/abstract/PMC/5432122

Philip Kuriakose

17

object named as

Philip Kuriakose

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

http://europepmc.org/abstract/PMC/5432122

author name string

Yasmin Abaza

4

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

http://europepmc.org/abstract/PMC/5432122

James Essell

6

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

http://europepmc.org/abstract/PMC/5432122

Roger M Lyons

7

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

http://europepmc.org/abstract/PMC/5432122

Michael Maris

9

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

http://europepmc.org/abstract/PMC/5432122

Brian Heller

10

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

http://europepmc.org/abstract/PMC/5432122

Sunil Babu

12

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

http://europepmc.org/abstract/PMC/5432122

David Wright

13

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

http://europepmc.org/abstract/PMC/5432122

Bertrand Anz

14

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

http://europepmc.org/abstract/PMC/5432122

Ralph Boccia

15

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

http://europepmc.org/abstract/PMC/5432122

James Reeves

18

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

http://europepmc.org/abstract/PMC/5432122

Richard Ghalie

21

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

http://europepmc.org/abstract/PMC/5432122

language of work or name

0 references

publication date

17 January 2017

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

http://europepmc.org/abstract/PMC/5432122

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

http://europepmc.org/abstract/PMC/5432122

123

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

http://europepmc.org/abstract/PMC/5432122

6

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

http://europepmc.org/abstract/PMC/5432122

994-1002

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

http://europepmc.org/abstract/PMC/5432122

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432122

15 June 2018

Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432122

15 June 2018

Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432122

15 June 2018

Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432122

15 June 2018

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432122

15 June 2018

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432122

15 June 2018

Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432122

15 June 2018

Revised international prognostic scoring system for myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432122

15 June 2018

Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432122

15 June 2018

Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432122

15 June 2018

Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissue

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432122

15 June 2018

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432122

15 June 2018

A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432122

15 June 2018

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432122

15 June 2018

Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432122

15 June 2018

CpG island methylation and histone modifications: biology and clinical significance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432122

15 June 2018

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432122

15 June 2018

Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432122

15 June 2018

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432122

15 June 2018

DNA methylation models histone acetylation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432122

15 June 2018

International scoring system for evaluating prognosis in myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432122

15 June 2018

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432122

20 August 2018

A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432122

20 August 2018

TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432122

20 August 2018

Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432122

20 August 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30533

21 January 2018

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30533

21 January 2018

Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30533

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30533

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30533

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.30533

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

http://europepmc.org/abstract/PMC/5432122

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

http://europepmc.org/abstract/PMC/5432122

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

24 May 2018

http://europepmc.org/abstract/PMC/5432122

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40377702&oldid=1896461405"